Immunic, Inc. Announces Proposed Public Offering

Core Viewpoint - Immunic, Inc. has initiated an underwritten public offering of various warrants to purchase shares of common stock, aimed at funding clinical trials and operations for its pipeline of therapies targeting chronic inflammatory and autoimmune diseases [1][2]. Group 1: Offering Details - The public offering includes pre-funded warrants, Series A warrants expiring on December 31, 2025, and Series B warrants expiring five years after issuance [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or the actual size and terms [1]. - Leerink Partners is acting as the sole bookrunner for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to fund clinical trials, operations, and other general corporate purposes [2]. Group 3: Company Overview - Immunic, Inc. is focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases [5]. - The lead program, vidofludimus calcium (IMU-838), is in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026 [5]. - Vidofludimus calcium has shown therapeutic activity in earlier phase 2 trials and works as a first-in-class nuclear receptor related 1 (Nurr1) activator [5]. - Other candidates include IMU-856, targeting gastrointestinal diseases, and IMU-381, currently in preclinical testing [5].